title: Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression.
abstract: In three patients with trazodone-resistant unipolar depression, carbamazepine 400 mg/day was co-administered for 4 weeks. They all showed favourable responses; two non-delusional patients completely or almost recovered, while one delusional patient showed considerable improvement in depressive symptoms other than delusions of guilt. Plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine (m-CPP) were decreased, while the m-CPP/trazodone ratio was increased in all cases. The present report suggests that carbamazepine augments antidepressant effects of trazodone by an enhancement of serotonin function.
authors.affiliation: Department of Neuropsychiatry, Hirosaki University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Otani
authors.forename: N
authors.initials: N
authors.lastname: Yasui
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.forename: T
authors.initials: T
authors.lastname: Ohkubo
authors.forename: T
authors.initials: T
authors.lastname: Osanai
authors.forename: K
authors.initials: K
authors.lastname: Sugawara
mesh_terms: D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D014196:Trazodone / Q000009:adverse effects*
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone